Download PDF
Homeopathy 2009; 98(02): 114-121
DOI: 10.1016/j.homp.2009.02.004
Education and Debate
Copyright © The Faculty of Homeopathy 2009

Antidepressants, suicidality and rebound effect: evidence of similitude?

Marcus Zulian Teixeira
Subject Editor:
Further Information

Publication History

Received13 August 2007
revised14 January 2009

accepted04 February 2009

Publication Date:
15 December 2017 (online)

    Permissions and Reprints

Background: Samuel Hahnemann noticed that palliative treatments for the symptoms of chronic diseases, after an initial improvement, provoked symptoms similar but stronger symptoms to those initially suppressed. He regarded this as a consequence of the vital reaction of the organism: an automatic and instinctive capacity to return to the initial health condition altered by medicines. Using this homeostatic conception of the organism as a treatment rationale, Hahnemann proposed the therapy of similarity, administering to the patients medicines capable of causing, in healthy individuals, similar symptoms to the natural disease. Based on experimental observations, he proposed that the primary action of the drug was followed by the secondary and opposite action of the organism, inaugurating homeopathic pharmacology, and alerting to the harmful consequences of palliative medicines in susceptible individuals. Such iatrogenic events can be observed in contemporary medicine, after the withdrawal of modern enantiopathic medicines, according to the study of the rebound effect or paradoxical reaction of the organism.

Method: This study reviews the recent studies which describe suicidality after the suspension or discontinuation of second generation antidepressants according to the hypothesis of the paradoxical reaction of the organism.

Conclusions: Rebound and withdrawal effects, including suicidality occur with antidepressant drugs. They are relatively rare but more intense than the primary action of the drug. The probability of such effects is influenced by patient factors including age and diagnosis, and drug factors including half-life.

Keywords

similitude - homeopathic medicines - secondary effect - rebound effect - paradoxical reaction - withdrawal syndrome - antidepressant - suicide
 

  • References

  • 1 Hahnemann S. Essay on a new principle for ascertaining the curative power of drugs, and some examinations of the previous principles. Hufeland's J 1796; 2: 391
    PubMedGoogle Scholar
  • 2 Hahnemann S. Organon of medicine. [Boericke W, Trans.] 6th edn. New Delhi: B Jain Publishers; 1991.
    Google Scholar
  • 3 Mittelstaedt P., Weingartner P. Laws of nature. [Are the laws of logic laws of nature?, Part I, pages 27–47] Heidelberg: Springer; 2005.
    Google Scholar
  • 4 Teixeira M.Z. Semelhante cura semelhante: o princípio de cura homeopático fundamentado pela racionalidade médica e científica. Similar cures similar: the homeopathic cure principle based by the medical and scientific rationality. São Paulo: Editorial Petrus; 1998.
    Google Scholar
  • 5 Teixeira M.Z. Similitude in modern pharmacology. Homeopathy 1999; 88 (03) 112-120.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Teixeira M.Z. Homeopathic use of modern medicines: utilisation of the curative rebound effect. Med Hypotheses 2003; 60 (02) 276-283.
    CrossrefPubMedGoogle Scholar
  • 7 Teixeira M.Z. ‘Paradoxical strategy for treating chronic diseases’: a therapeutic model used in homeopathy for more than two centuries. Homeopathy 2005; 94 (04) 265-266.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Teixeira M.Z. Evidence of the principle of similitude in modern fatal iatrogenic events. Homeopathy 2006; 95 (04) 229-236.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Teixeira M.Z. NSAIDs, myocardial infarction, rebound effect and similitude. Homeopathy 2007; 96 (01) 67-68.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Teixeira M.Z. Bronchodilators, fatal asthma, rebound effect and similitude. Homeopathy 2007; 96 (02) 135-137.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Hodding G.C., Jann M., Ackerman I.P. Drug withdrawal syndromes – a literature review. West J Med 1980; 133: 383-391.
    PubMedGoogle Scholar
  • 12 Wolfe R.M. Antidepressant withdrawal reactions. Am Fam Physician 1997; 56 (02) 455-462.
    PubMedGoogle Scholar
  • 13 Oniani T.N., Akhvlediani G.R. Influence of some monoamine oxidase inhibitors on the sleep-wakefulness cycle of the cat. Neurosci Behav Physiol 1988; 18 (04) 301-306.
    CrossrefPubMedGoogle Scholar
  • 14 Kupfer D.J., Pollock B.G., Perel J.M., Miewald J.M., Grochocinski V.J., Ehlers C.L. Effect of pulse loading with clomipramine on EEG sleep. Psychiatry Res 1994; 54 (02) 161-175.
    CrossrefPubMedGoogle Scholar
  • 15 Smith R.L., Barrett R.J., Sanders-Bush E. Neurochemical and behavioral evidence that quipazine-ketanserin discrimination is mediated by serotonin2A receptor. J Pharmacol Exp Ther 1995; 275 (02) 1050-1057.
    PubMedGoogle Scholar
  • 16 Borrelli B., Spring B., Niaura R., Kristeller J., Ockene J.K., Keuthen N.J. Weight suppression and weight rebound in ex-smokers treated with fluoxetine. J Consult Clin Psychol 1999; 67 (01) 124-131.
    CrossrefPubMedGoogle Scholar
  • 17 Pace-Schott E.F., Gersh T., Silvestri R., Stickgold R., Salzman C., Hobson J.A. SSRI treatment suppresses dream recall frequency but increases subjective dream intensity in normal subjects. J Sleep Res 2001; 10 (02) 129-142.
    CrossrefPubMedGoogle Scholar
  • 18 D'Aquila P.S., Panin F., Serra G. Long-term imipramine withdrawal induces a depressive-like behaviour in the forced swimming test. Eur J Pharmacol 2004; 492 (01) 61-63.
    CrossrefPubMedGoogle Scholar
  • 19 Lerman C., Niaura R., Collins B.N. et al. Effect of bupropion on depression symptoms in a smoking cessation clinical trial. Psychol Addict Behav 2004; 18 (04) 362-366.
    CrossrefPubMedGoogle Scholar
  • 20 Huang X.F., Han M., Huang X., Zavitsanou K., Deng C. Olanzapine differentially affects 5-HT2A and 2C receptor mRNA expression in the rat brain. Behav Brain Res 2006; 171 (02) 355-362.
    CrossrefPubMedGoogle Scholar
  • 21 Lader M. Pharmacotherapy of mood disorders and treatment discontinuation. Drugs 2007; 67 (12) 1657-1663.
    CrossrefPubMedGoogle Scholar
  • 22 Schatzberg A., Haddad P., Kaplan E. et al. Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. J Clin Psychiatry 1997; 58 (Suppl. 07) 5-10.
    PubMedGoogle Scholar
  • 23 Tamam L., Ozpoyraz N. Selective serotonin reuptake inhibitor discontinuation syndrome: a review. Adv Ther 2002; 19 (01) 17-26.
    CrossrefPubMedGoogle Scholar
  • 24 Price J., Waller P., Wood S., MacKay A.V. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol 1996; 42 (06) 757-763.
    PubMedGoogle Scholar
  • 25 Haddad P., Anderson I., Rosenbaum J.F. Antidepressant discontinuation syndromes. Haddad P., Dursun S., Deakin B. Adverse Syndromes and Psychiatric Drugs. 2004. Oxford: Oxford University Press; 184-205
    Google Scholar
  • 26 Weller I. Report of the committee on safety of medicines expert working group on the safety of selective serotonin reuptake inhibitor antidepressants. London: London Stationery Office; 2005.
    Google Scholar
  • 27 Rosenbaum J.F., Fava M., Hoog S.L., Ascroft R.C., Krebs W.B. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomised clinical trial. Biol Psychiatry 1998; 44 (02) 77-87.
    CrossrefPubMedGoogle Scholar
  • 28 Hindmarch I., Kimber S., Cockle S. Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance. Int Clin Psychopharmacol 2000; 15 (06) 305-318.
    CrossrefPubMedGoogle Scholar
  • 29 Judge R., Parry M., Quail D., Jacobson J.G. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. Int Clin Psychopharmacol 2002; 17 (05) 217-225.
    CrossrefPubMedGoogle Scholar
  • 30 Zajecka J., Fawcett J., Amsterdam J. et al. Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study. J Clin Psychopharmacol 1998; 18 (03) 193-197.
    CrossrefPubMedGoogle Scholar
  • 31 Baldwin D., Montgomery S.A., Nil R., Lader M. Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol 2007; 10 (01) 73-84.
    CrossrefPubMedGoogle Scholar
  • 32 Harvey B.H., Retief R., Korff A., Wegener G. Increased hippocampal nitric oxide synthase activity and stress responsiveness after imipramine discontinuation: role of 5HT 2A/C-receptors. Metab Brain Dis 2006; 21 (02/03) 211-220.
    CrossrefPubMedGoogle Scholar
  • 33 Coupland N.J., Bell C.J., Potokar J.P. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996; 16 (05) 356-362.
    CrossrefPubMedGoogle Scholar
  • 34 Hammad T.A., Laughren T., Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006; 63 (03) 332-339.
    CrossrefPubMedGoogle Scholar
  • 35 March J., Silva S., Petrycki S. et al. Treatment for adolescents with depression study team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: treatment for adolescents with depression study (TADS) randomized controlled trial. JAMA 2004; 292 (07) 807-820.
    CrossrefPubMedGoogle Scholar
  • 36 Bridge J.A., Iyengar S., Salary C.B. et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007; 297 (15) 1683-1696.
    CrossrefPubMedGoogle Scholar
  • 37 Baldessarini R.J., Pompili M., Tondo L. Suicidal risk in antidepressant drug trials. Arch Gen Psychiatry 2006; 63 (03) 246-248.
    CrossrefPubMedGoogle Scholar
  • 38 Dopheide J.A. Recognizing and treating depression in children and adolescents. Am J Health Syst Pharm 2006; 63 (03) 233-243.
    CrossrefPubMedGoogle Scholar
  • 39 U.S. Food and Drug Administration. FDA Public Health Advisory (May 2, 2007): “FDA proposes new warnings about suicidal thinking, behavior in young adults who take antidepressant medications”. Available from: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01624.html
    PubMedGoogle Scholar
  • 40 Vaswani M., Linda F.K., Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27 (01) 85-102.
    CrossrefPubMedGoogle Scholar